


CZC-25146

Cat. No.:	HY-15800A		
CAS No.:	1191911-26-8		
Molecular Formula:	C ₂₂ H ₂₅ FN ₆ O ₄ S		
Molecular Weight:	488.54		
Target:	LRRK2		
Pathway:	Autophagy		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 46 mg/mL (94.16 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.0469 mL	10.2346 mL	20.4692 mL
	5 mM	0.4094 mL	2.0469 mL	4.0938 mL
	10 mM	0.2047 mL	1.0235 mL	2.0469 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

CZC-25146 is a potent and orally active LRRK2 inhibitor with IC₅₀ values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 can be used to research Parkinson's disease and liver diseases^{[1][2][3]}.

IC₅₀ & Target

IC₅₀: 4.76 nM (wild-type LRRK2), 6.87 nM (G2019S LRRK2)^[1]

In Vitro

CZC-25146 (0.01-5 μM; 7 days) does not cause cytotoxicity in human cortical neurons, nor blocking neuronal development^[1].

CZC-25146 (0.01-5 μ M; 2 days) potently attenuates G2019S LRRK2-mediated toxicity in primary rodent neurons in a concentration-dependent manner with an EC₅₀ of ~100 nM^[1].
 CZC-25146 (0.06-1000 nM) rescues LRRK2 G2019S-induced neurite defects in primary human neurons in a dose-dependent manner^[1].
 CZC-25146 (14.3 and 28.6 μ M; 48 h) markedly reduces The mutant AAT encoded by the Z allele (ATZ) polymer load and restores AAT secretion in iPSC-Hepatocyte, without compromising cell viability^[3].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
 Cell Cytotoxicity Assay^[1]

Cell Line:	Human cortical neurons
Concentration:	0.01, 0.1, 1 and 5 μ M
Incubation Time:	7 days
Result:	Did not cause cytotoxicity in human cortical neurons at concentrations below 5 μ M over a seven-day treatment in culture, nor did it block neuronal development.

In Vivo

CZC-25146 (250 mg/kg; p.o.; 14 days) reduces the ATZ polymer levels in over expressing human polymeric ATZ mice^[3].
 CZC-25146 (1 mg/kg for i.v.; 5 mg/kg for p.o.; single dosage) exhibits relatively good pharmacokinetic properties and an extensive distribution throughout animal body following intravenous injection into mice^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Genetically modified male mice (6 weeks; over expressing human polymeric ATZ) ^[3]
Dosage:	250 mg/kg
Administration:	p.o.; 14 days
Result:	Dramatically and reproducibly reduced the ATZ polymer levels with an overall reduction from 60% in the control group to 37%.

Animal Model:	Male CD-1 mice ^[1]	
Dosage:	1 mg/kg for i.v.; 5 mg/kg for p.o.	
Administration:	i.v. and p.o.; single dosage	
Result:	Pharmacokinetic Parameters of CZC-25146 in male CD-1 mice ^[1] .	
	i.v. (1 mg/kg)	p.o. (5 mg/kg)
CL (L/h/kg)	2.3	
V _{ss} (L/kg)	5.4	
t _{1/2} (h)	1.6	1
t _{max} (h)	0	0.25
C _{max} (ng/mL)	154	1357

	AUC _{last} (ng/mL·h)	419	2878
	AUC _{inf} (ng/mL·h)	434	2894
	F (%)		133

REFERENCES

- [1]. Atashrazm F, et al. LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives. Clin Pharmacol. 2016 Oct 20;8:177-189.
- [2]. Deniz Kent, et al. Small molecule screen employing patient-derived iPS hepatocytes identifies LRRK2 as a novel therapeutic target for Alpha1 Antitrypsin Deficiency.
- [3]. Ramsden N, et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol. 2011 Oct 21;6(10):1021-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA